{
    "id": "5c5b52731a4c55d80b000003",
    "question": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the relationship between deletion at 6q24.2-26 and its impact on survival rates in patients with high-grade serous ovarian carcinoma (HGSOCs). The relevant documents do not explicitly state that deletion at 6q24.2-26 is associated with longer survival in HGSOCs. In fact, the documents suggest that TP53 mutations are virtually ubiquitous in high-grade serous cancers, which may indicate a poor prognosis. However, there is no direct information about the specific chromosomal deletion at 6q24.2-26 and its correlation with survival rates in HGSOCs. The documents do mention that molecular alterations, including mutations and deletions, can impact prognosis, but they do not provide a clear link between the deletion at 6q24.2-26 and improved survival in HGSOCs. Therefore, based on the available information, we cannot conclude that deletion at 6q24.2-26 is associated with longer survival in HGSOCs.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Gynecology_Novak_7200",
            "title": "Gynecology_Novak",
            "content": "CHAPTER 37 Ovarian, Fallopian Tube, and Peritoneal Cancer Figure 37.9 BRCA1-associated ovarian carcinoma is typically a high-grade serous adenocarcinoma with numerous mitotic figures and marked nuclear pleomorphism. A brisk lymphocytic infiltrate with tumor infiltrating lymphocytes is not uncommon in these tumors. The risk of carrying a germline mutation that predisposes to ovarian cancer depends on the number of first-or second-degree relatives (or both) with a history of epithelial ovarian carcinoma or breast cancer (or both) and on the number of malignancies that occurs at an earlier age. The degree of risk is difficult to determine precisely unless a full pedigree analysis is performed. 1. In families with two first-degree relatives (i.e., mother, sister, or daughter) with documented premenopausal epithelial ovarian cancer, the risk that a female first-degree relative has an affected gene could be as high as 35% to 40% (60). 2."
        },
        {
            "id": "Gynecology_Novak_7161",
            "title": "Gynecology_Novak",
            "content": "Although it was believed that epithelial ovarian cancers arise from either the surface epithelium of the ovary or from inclusion cysts within the ovary, there is growing evidence to suggest that many, if not most, high-grade serous carcinomas of the ovary arise from the fimbrial end of the fallopian tube rather than from the ovary (4,5). It is suggested that serous epithelial ovarian cancers be separated into two distinct groups\u2014type I and type II serous tumors\u2014as they differ considerably in the cell of origin, molecular pathogenesis, and their biological behavior (6). Type I tumors include serous borderline tumors and low-grade serous carcinoma; they are genetically stable and are characterized by mutations in KRAS and BRAF. Type II serous tumors are rapidly growing, highly aggressive neoplasms that lack well-defined precursor lesions; most are advanced stage at, or soon after, their inception and many appear to arise in the fimbrial end of the fallopian tube (7). The type II tumors"
        },
        {
            "id": "Gynecology_Novak_584",
            "title": "Gynecology_Novak",
            "content": "65. Baker VV. Update on the molecular carcinogenesis of cervix cancer. Clin Consult Obstet Gynecol 1995;7:86\u201393. 66. Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66\u201373. 67. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260\u2013 2265. 68. Bacolod MD, Schemmann GS, Giardina SF, et al. Emerging paradigms in cancer genetics: some important findings from high- density single nucleotide polymorphism array studies. Cancer Res 2009;69:723\u2013727. 69. Goode EL, Maurer MJ, Sellers TA, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010;16:995\u20131007. 70."
        },
        {
            "id": "Surgery_Schwartz_12010",
            "title": "Surgery_Schwartz",
            "content": "frequent, and they include bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms of urgency or frequency,117 which form the basis of an ovarian cancer symptom index (Table 41-10). When newly developed and persistent, these symptoms should prompt an evaluation specifically targeted for identification of gynecologic malignancy.The histologic heterogeneity of ovarian cancer has long been recognized, but with the emergence of more robust clini-copathologic, molecular, and genetic data over the past decade these distinctions have become more clearly defined. Type I tumors consist of low-grade serous (LGS), low-grade endome-trioid, clear cell carcinomas (CCC), and mucinous carcinomas and are characterized by mutations in KRAS, BRAF, PTEN, PIK3CA, CTNNB1, ARID1A, and PPP2R1A. Type II ovarian cancers are the most common of the ovarian cancer histotypes, consisting of high-grade serous (70%), high-grade endometri-oid, carcinosarcoma, and"
        },
        {
            "id": "InternalMed_Harrison_7525",
            "title": "InternalMed_Harrison",
            "content": "Considerable evidence now suggests that the precursor cell to serous carcinoma of the ovary might actually arise in the fimbria of the fallopian tube with extension or metastasis to the ovarian surface or capture of preneoplastic or neoplastic exfoliating tubal cells into an involuting ovarian follicle around the time of ovulation. Careful histologic and molecular analysis of tubal epithelium demonstrates molecular and histologic abnormalities, termed serous tubular intraepithelial carcinoma (STIC) lesions, in a high proportion of women undergoing risk-reducing salpingo-oophorectomies in the context of high-risk germline mutations in BRCA1 and BRCA2, as well as a modest proportion of women with ovarian cancer in the absence of such mutations. Genetic Risk Factors A variety of genetic syndromes substan tially increase a woman\u2019s risk of developing ovarian cancer."
        },
        {
            "id": "Pathology_Robbins_4330",
            "title": "Pathology_Robbins",
            "content": "Once thought to be uncommon, primary adenocarcinomas of the fallopian tube may be the site of origin for many of the high-grade serous carcinomas long thought to arise in the ovary. Studies have identified the presence of serous tubal intraepithelial carcinoma (STIC) in the fimbriated ends of fallopian tubes. Like the precursor of uterine serous carcinoma, STICs have mutations in TP53 in more than 90% of cases. These lesions are found frequently in fallopian tubes removed prophylactically from women who carry mutations in BRCA1 and BRCA2 and less commonly in instances where tubes are removed from women without known genetic risk factors. This has led to the idea that sporadic \u201covarian\u201d serous carcinomas (discussed later) also originate in the fallopian tube. Because the fimbriated end of the fallopian tube is intimately associated with the ovary and has access to the peritoneal cavity, fallopian tube carcinomas frequently involve the ovary, omentum, and peritoneal cavity at"
        },
        {
            "id": "Surgery_Schwartz_12011",
            "title": "Surgery_Schwartz",
            "content": "PIK3CA, CTNNB1, ARID1A, and PPP2R1A. Type II ovarian cancers are the most common of the ovarian cancer histotypes, consisting of high-grade serous (70%), high-grade endometri-oid, carcinosarcoma, and undifferentiated carcinomas. Type II tumors are defined by TP53 mutations, which are rare in type I cancers.118-121 Each of these types have distinct risk factors and potential precursor lesions.121Risk factors for development of ovarian cancer include hormonal factors such as early menarche, late menopause, and nulliparity. The use of oral contraceptives reduces risk of ovar-ian carcinoma\u2014this risk reduction persists for up to 30 years after cessation of use.122 Additionally, tubal ligation and hyster-ectomy decrease population level epithelial ovarian cancer risk. Genetic predisposition to breast or ovarian cancer is the most important known risk for the development of ovarian cancer, and 18% to 24% of ovarian carcinomas may arise in conjunction with a hereditary predisposition.123-128"
        },
        {
            "id": "Pathology_Robbins_4334",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net Table 19.3 Frequency of Major Ovarian Tumors Some ovarian epithelial tumors fall into an intermediate category currently referred to as borderline tumors. Although the majority of borderline tumors behave in a benign manner they can recur and some can progress to carcinoma. Important risk factors for ovarian cancer include nulliparity, family history, and germline mutations in certain Fig. 19.15 Derivation, of various ovarian neoplasms. Type I tumors progress from benign tumors through borderline tumors that may give rise to a low-grade carcinoma. Type II tumors arise from inclusions cysts/fallopian tube epithelium via intraepithelial precursors that are often not identified. They demonstrate high-grade features and are most commonly of serous histology. STIC, serous tubal intraepithelial carcinoma."
        },
        {
            "id": "Surgery_Schwartz_12025",
            "title": "Surgery_Schwartz",
            "content": "after surgery. Diagnostic laparoscopic evaluation prior to cytoreductive surgery has been suggested as a means to avoid unnecessary laparotomy, resulting in subop-timal cytoreduction. Patients deemed not to be candidates for cytoreduction could proceed immediately to NACT at the time of tissue collection for definitive diagnosis. A Fagotti predictive index \u22658 (Table 41-13) is a predictor of suboptimal cytoreduc-tion in advanced ovarian cancer with reasonable sensitivity and high specificity.149 These recommendations currently apply to HGSOC, clear cell cancer, and high-grade endometrioid ovarian Brunicardi_Ch41_p1783-p1826.indd 181718/02/19 4:35 PM 1818SPECIFIC CONSIDERATIONSPART IIcancers. Low-grade tumors are less chemotherapy sensitive, and primary surgical resection is recommended when feasible. Standard of care adjuvant therapy of advanced stage epithe-lial ovarian cancer remains intravenous platinumand tax-ane-based chemotherapy.150 In 2006, the National Cancer Institute"
        },
        {
            "id": "Gynecology_Novak_7438",
            "title": "Gynecology_Novak",
            "content": "As noted above, there is growing evidence to suggest that many high-grade serous carcinomas of the ovary may prove to arise from the fimbrial end of the fallopian tube (5,7). The true incidence of fallopian tube cancer may be historically underestimated because of the convention of assigning many of these as ovarian cancer when the site of origin is unclear. Despite the uncertainty concerning site of origin, all evidence suggests that our evaluation and treatment of these high-grade serous carcinomas should be the same. In recognition of this, many pathologists resorted to diagnosing these tumors as (nonuterine) high-grade serous carcinomas without definite assignment to primary site. (iii) a pelvic mass. This triad is noted in fewer than 15% of patients, and may be less common based on the histopathologic origins of fallopian tube cancers (3)."
        },
        {
            "id": "Gynecology_Novak_7179",
            "title": "Gynecology_Novak",
            "content": "Peritoneal Carcinomas Peritoneal tumors are histologically indistinguishable from ovarian serous tumors. In the case of borderline serous peritoneal tumors and serous peritoneal carcinomas, the ovaries are normal or minimally involved, and the tumors affect predominantly the uterosacral ligaments, pelvic peritoneum, or omentum. The overall prognosis for borderline serous peritoneal tumors is excellent and comparable to that of ovarian borderline serous tumors (25\u201327). In the review of 38 cases of peritoneal borderline serous tumors from the literature, 32 women had no persistent disease, 4 were well after resection of recurrence, 1 developed an invasive serous carcinoma, and 1 died from the effects of the tumor (25)."
        },
        {
            "id": "Gynecology_Novak_7178",
            "title": "Gynecology_Novak",
            "content": "Figure 37.7 Clear cell carcinoma of the ovary. Note the solid variant of clear cell carcinoma with sheets of cells that have clear cytoplasm (\u201chobnail\u201d cells). The designation transitional cell carcinoma refers to a primary ovarian carcinoma resembling transitional cell carcinoma of the urinary bladder without a recognizable Brenner tumor. It is reported that those ovarian carcinomas that contain more than 50% of transitional cell carcinoma are more sensitive to chemotherapy and have a more favorable prognosis than other poorly differentiated ovarian carcinomas of comparable stage (22,23). Transitional cell tumors differ from malignant Brenner tumors in that they are more frequently diagnosed in an advanced stage and are associated with a poorer survival rate (24)."
        },
        {
            "id": "Gynecology_Novak_7210",
            "title": "Gynecology_Novak",
            "content": "The role of hysterectomy is more controversial. Most studies show no increase in the rate of uterine and cervical tumors, but there are rare reports of an increase of papillary serous tumors of the endometrium (83). Women on tamoxifen are at higher risk for benign endometrial lesions (e.g., polyps) and endometrial cancer. It is reasonable to consider the performance of a prophylactic hysterectomy in conjunction with salpingo-oophorectomy, but this decision should be individualized. The survival of women who have a BRCA1 or BRCA2 mutation and develop ovarian cancer is longer than that for those who do not have a mutation. In one study, the median survival for mutation carriers was 53.4 months compared with 37.8 months for those with sporadic ovarian cancer from the same institution (84). Current recommendations for management of women at high risk for ovarian cancer are summarized as follows (72,82): 1."
        },
        {
            "id": "InternalMed_Harrison_7722",
            "title": "InternalMed_Harrison",
            "content": "The term primary peritoneal papillary serous carcinoma (PPSC) has been used to describe CUP with carcinomatosis with the pathologic and laboratory (elevated CA-125 antigen) characteristics of ovarian cancer but no ovarian primary tumor identified on transvaginal sonography or laparotomy. Studies suggest that ovarian cancer and PPSC, which are both of m\u00fcllerian origin, have similar gene expression profiles. Similar to patients with ovarian cancer, patients with PPSC are candidates for cytoreductive surgery, followed by adjuvant taxaneand platinum-based chemotherapy. In one Chapter 120e Carcinoma of Unknown Primary"
        },
        {
            "id": "Gynecology_Novak_4221",
            "title": "Gynecology_Novak",
            "content": "Based on the finding that many serous carcinomas arise in the fallopian tube rather than in the ovary, it was proposed that bilateral salpingectomy with ovarian conservation should be performed in patients with these high penetrance germline mutations while awaiting more definitive surgical intervention (30,31). One could consider this in women at average risk for these tumors when they undergo hysterectomy for benign disease. It is unknown whether this would substantially decrease the risk of developing these malignancies. Although salpingo-oophorectomy can be accomplished by laparoscopy or laparotomy in virtually 100% of cases, the success rate for vaginal hysterectomy ranges from 65% to 95% for experienced vaginal surgeons (32,33)."
        },
        {
            "id": "Gynecology_Novak_7449",
            "title": "Gynecology_Novak",
            "content": "13. McCaughey WT, Kirk ME, Lester W, et al. Peritoneal epithelial lesions associated with proliferative serous tumours of the ovary. Histopathology 1984;8:195\u2013208. 14. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long term (>5 year) follow-up. Am J Surg Pathol 2005;29:707\u2013723. 15. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31:539\u2013557. 16. Michael H, Roth LM. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 1986;57:1240\u2013 1247. 17. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65:578\u2013585. 18. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990;21:397\u2013403. 19."
        },
        {
            "id": "Gynecology_Novak_6831",
            "title": "Gynecology_Novak",
            "content": "233. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177\u2013185. 234. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. PNAS 2003;100:5908\u20135913. 235. Tashiro H, Lax SF, Gaudin PB, et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997;150:75\u2013 79. 236. Saffari B, Jones LA, Elnaggar A, et al. Amplification and overexpression of Her-2/Neu (C-Erbb2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693\u20135698. 237. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122\u2013126. 238."
        },
        {
            "id": "Gynecology_Novak_6615",
            "title": "Gynecology_Novak",
            "content": "Synchronous endometrial and ovarian cancers are the most frequent simultaneously occurring genital malignancies, with a reported incidence of 1.4% to 3.8% (118\u2013122). Most commonly, both the ovarian and endometrial tumor are well-differentiated endometrioid adenocarcinomas of low stage, resulting in an excellent prognosis. Patients often are premenopausal and present with abnormal uterine bleeding. The ovarian cancer usually is discovered as an incidental finding and is diagnosed at an earlier stage because of the symptomatic endometrial tumor, leading to a more favorable outcome. Up to 29% of patients with endometrioid ovarian adenocarcinomas have associated endometrial cancer. If more poorly differentiated, nonendometrioid histologic subtypes are present or if the uterine and ovarian tumors are histologically dissimilar, the prognosis is less favorable. Immunohistochemical studies, \ufb02ow cytometry, and assessment of molecular DNA patterns to detect loss of heterozygosity may be helpful"
        },
        {
            "id": "Pathology_Robbins_4341",
            "title": "Pathology_Robbins",
            "content": "The prognosis for patients with high-grade serous carcinoma is poor, even after surgery and chemotherapy, and depends heavily on the stage of the disease at diagnosis. The 5-year survival for women with carcinoma confined to one ovary is about 90%, but falls precipitously with higher stage tumors to less than 40% depending on the exact stage. In contrast, borderline tumors are associated with nearly 100% survival. Of note, women with tumors containing BRCA1/2 mutations tend to have a better prognosis than women whose tumors lack these genetic abnormalities. Mucinous tumors differ from serous tumors in two respects: the neoplastic epithelium consists of mucin-secreting cells; and mucinous tumors are considerably less likely to be malignant. Overall, only 10% of mucinous tumors are malignant; another 10% are borderline, and 80% are benign."
        },
        {
            "id": "Gynecology_Novak_7170",
            "title": "Gynecology_Novak",
            "content": "Serous Carcinomas In malignant serous tumors, stromal invasion is present (2). The grade of tumor is important and needs to be documented. In low-grade serous adenocarcinomas, papillary and glandular structures predominate (Fig. 37.3); high-grade neoplasms are characterized by solid sheets of cells, nuclear pleomorphism, and high mitotic activity (Fig. 37.4). Laminated, calcified psammoma bodies are found in 80% of serous carcinomas. Serous psammocarcinoma is a rare variant of serous carcinoma characterized by massive psammoma body formation and low-grade cytological features. At least 75% of the epithelial nests are associated with psammoma body formation. Patients with serous psammocarcinoma have a protracted clinical course and a relatively favorable prognosis; their clinical course more closely resembles that of high-stage, progressive serous borderline tumor than serous carcinoma."
        },
        {
            "id": "Surgery_Schwartz_12014",
            "title": "Surgery_Schwartz",
            "content": "precursor lesion. In 2001, however, \u201cdysplastic changes\u201d in the fallopian tubes removed from women with increased risk of developing ovarian carcinoma were first described.136 Subse-quent careful microscopic examination using a newly developed \u201csectioning and extensively examining of the fimbriated end\u201d protocol (SEE-FIM) of the grossly normal fallopian tubes and ovaries from women with BRCA1/2 mutations revealed occult tubal cancer and precancers designated as serous tubal intraepi-thelial carcinoma. The relationship between serous tubal intraep-ithelial carcinomas and high-grade serous and endometrioid cancers is supported by the ubiquitous presence of TP53 muta-tions and their typical location within the fimbriated end of the fallopian tube.118,121,137 High-grade, serous epithelial cancers of the ovary, fallopian tube, and peritoneum are now recognized to have a common fallopian tubal precursor lesion and often com-bined under the rubric of epithelial ovarian cancer (HGSOC).For"
        },
        {
            "id": "Gynecology_Novak_536",
            "title": "Gynecology_Novak",
            "content": "Point mutations in the BRCA1 and BRCA2 genes can alter the activity of these genes and predispose to the development of breast and ovarian cancer (67). The frequency of BRCA1 and BRCA2 mutations in the general population in the United States is estimated at 1:250. Specific Figure 6.9 Genes can be amplified or undergo mutation, deletion, or rearrangement. founder mutations were reported for various ethnic groups. For example, two BRCA1 mutations (185delAG and 5382insC) and one BRCA2 mutation (6174delT) are found in 2.5% of Ashkenazi Jews of Central and Eastern European descent. Additional founder mutations were described in other ethnic groups, including from the Netherlands (BRCA1, 2804delAA and several large deletion mutations), Iceland (BRCA2, 995del5), and Sweden (BRCA1, 3171ins5)."
        },
        {
            "id": "Gynecology_Novak_7473",
            "title": "Gynecology_Novak",
            "content": "122. Berek JS, Mart\u00b4ez-Maza O, Hamilton T, et al. Molecular and biological factors in the pathogenesis of ovarian cancer. Ann Oncol 1993;4:S3\u2013S16. 123. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138\u20131150. 124. Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival measured with log (relative risk) as main objectives. Eur J Cancer Clin Oncol 1989;25:711\u2013720. 125. van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ATM, et al. Predictability of the survival of patients with ovarian cancer. J Clin Oncol 1989;7:769\u2013773. 126. Berek JS, Bertlesen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statement. Ann Oncol 1999;10(Suppl 1):87\u201392. 127."
        },
        {
            "id": "Gynecology_Novak_7348",
            "title": "Gynecology_Novak",
            "content": "Survival The prognosis for patients with epithelial ovarian cancer is related to several clinical variables. Survival analyses based on prognostic variables are presented (1,3,30,123\u2013127). Including patients at all stages, patients younger than 50 years of age have a 5-year survival rate of about 40%, compared with about 15% for patients older than 50 years. The 5-year survival rate for carefully and properly staged patients with stage I disease is as high as 94%, for stage II is 73%, for stage III or IV 28% (1). The 5-year survival rate for stage IIIA is 41%, for stage IIIB about 25%, for stage IIIC 23%, and for stage IV disease 11% (Fig. 37.16). An analysis of the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) database reveals a trend toward improved survival for ovarian cancer in the United States. In this cohort, the survival for stage I was 93%, for stage II 70%, for stage III 37%, and for stage IV 25% (341)."
        },
        {
            "id": "Gynecology_Novak_6616",
            "title": "Gynecology_Novak",
            "content": "are histologically dissimilar, the prognosis is less favorable. Immunohistochemical studies, \ufb02ow cytometry, and assessment of molecular DNA patterns to detect loss of heterozygosity may be helpful in distinguishing between metastatic and independent tumors, but the differential diagnosis can usually be determined by conventional clinical and pathologic criteria."
        },
        {
            "id": "Gynecology_Novak_6658",
            "title": "Gynecology_Novak",
            "content": "and loss of heterozygosity (LOH) (216\u2013218). These distinct molecular alterations underscore prognostic differences. Type I endometrial cancer is limited to the uterus in 70% of cases with a 5-year survival greater than 85%. Type II endometrial cancer displays a more aggressive clinical course and a poor prognosis; even in tumors with little or no myometrial invasion, more than one in three patients will have extensive extrauterine spread with complete surgical staging, resulting in an overall survival of 20% (106,110,114,219)."
        },
        {
            "id": "Gynecology_Novak_7266",
            "title": "Gynecology_Novak",
            "content": "Stage I Epithelial Ovarian Cancer Early Stage, Low Risk Guthrie et al. studied the outcome of 656 patients with early-stage epithelial ovarian cancer (140). Patients who had stage IA, grade 1 cancer and did not receive radiation or chemotherapy did not die of their disease; indicating that adjuvant therapy is unnecessary. The GOG carried out a prospective, randomized trial of observation versus melphalan for patients with stage IA and IB, grades 1 and 2 disease (114). Five-year survival for each group was 94% and 96%, respectively, confirming that adjuvant treatment did not improve survival. Therefore, no adjuvant chemotherapy is recommended for these patients. Early Stage, High Risk"
        },
        {
            "id": "Gynecology_Novak_2568",
            "title": "Gynecology_Novak",
            "content": "Microsatellite DNA assays reveal an allelic imbalance (loss of heterozygosity) in p16 (Ink4), GALT, p53, and APOA2 loci in patients with endometriosis and in stage II of endometriosis (79). Another report found a loss of heterozygosity in 28% of endometriotic lesions at one or more sites: chromosomes 9p (18%), 11q (18%), and 22q (15%) (73)."
        },
        {
            "id": "Gynecology_Novak_7445",
            "title": "Gynecology_Novak",
            "content": "Table 37.9 FIGO Staging for Carcinoma of the Fallopian Tube FIGO, International Federation of Gynecology and Obstetrics. From Berek JS, Hacker NF. Berek and Hacker\u2019s Gynecologic Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2010:494; adapted from FIGO Annual Report. Vol 26, Int J Gynecol Obstet 2006;105:3\u20134. Prognosis The overall 5-year survival for patients with epithelial tubal carcinomas is about 40%. This number is higher than for patients with ovarian cancer and re\ufb02ects the somewhat higher proportion of patients diagnosed with early-stage disease. These data may re\ufb02ect the fact that some advanced stage tubal cancers were classified as ovarian cancers. The reported 5-year survival rate for patients with stage I disease is only about 65%. The 5-year survival rate for patients with stage II disease is 50% to 60%, but it is only 10% to 20% for patients with stages III and IV disease (480,485)."
        },
        {
            "id": "Pathology_Robbins_4337",
            "title": "Pathology_Robbins",
            "content": "There are two types of serous carcinomas, low-grade and high-grade. The former arise from benign or borderline lesions and progress slowly in a stepwise manner to become invasive carcinoma. These low-grade tumors are associated with mutations in genes encoding signaling proteins, such as KRAS, a member of the RAS gene family. The high-grade serous tumors develop rapidly. As already mentioned, many of these high-grade lesions arise in the fimbriated end of the fallopian tube via serous tubal intraepithelial carcinoma, rather than ovarian coelomic epithelium. TP53 mutations are virtually ubiquitous in high-grade serous cancers, being present in over 95% of cases. Other frequently mutated genes include the tumor suppressors NF1 and RB, as well as BRCA1 and BRCA2 in familial ovarian cancers."
        },
        {
            "id": "Surgery_Schwartz_12015",
            "title": "Surgery_Schwartz",
            "content": "cancers of the ovary, fallopian tube, and peritoneum are now recognized to have a common fallopian tubal precursor lesion and often com-bined under the rubric of epithelial ovarian cancer (HGSOC).For women at increased risk of ovarian cancer, the only confirmed prevention strategy is risk-reducing salpingo-oopherectomy.138,139 The lifetime risk of HGSOC is reduced to under 3% with risk-reducing salpingo-oopherectomy. A modern understanding of the fallopian tube as the site of origin for many ovarian cancers has led to the suggestion that opportunistic salpingectomy could be implemented as a potential cancer prevention strategy in the general population. Scandinavian population-based cohort studies have demon-strated a significant decrease in epithelial ovarian cancer following salpingectomy.140,141 Opportunistic salpingectomy is feasible among women undergoing tubal ligation, hysterectomy, or other pelvic surgery.142 Early Staged Ovarian Cancer. Early stage epithelial ovarian cancer"
        },
        {
            "id": "Gynecology_Novak_7169",
            "title": "Gynecology_Novak",
            "content": "Figure 37.3 Low-grade serous adenocarcinoma of the ovary. Clusters and papillae of malignant cells are in direct contact with fibrous stroma indicative of stromal invasion. The presence of stromal microinvasion is associated with lymphovascular space invasion in the primary ovarian tumor (and likely represents a form of true stromal invasion), but it is not associated with an aggressive clinical course, and patients with this finding should be managed in the same way as patients without stromal microinvasion."
        }
    ],
    "scores": [
        0.036105309035886976,
        0.030771368570391124,
        0.030748320897649284,
        0.02777955593489574,
        0.027367965133591403,
        0.025927083413714427,
        0.02579934685197843,
        0.02435055764481818,
        0.02401921303591647,
        0.02308945208711882,
        0.022846492552734902,
        0.022544513457556935,
        0.022142932427321706,
        0.021849473480793476,
        0.02108841258675446,
        0.021042103257763383,
        0.02029565555752933,
        0.019827956989247313,
        0.018978233495232956,
        0.01896117900790798,
        0.018750547621133797,
        0.018543956043956044,
        0.018265221017514596,
        0.0178585665311329,
        0.017427884615384616,
        0.016612399494983054,
        0.016471695576173187,
        0.01640364905899016,
        0.01618059633326809,
        0.01605392156862745,
        0.015783259802398558,
        0.015740740740740743
    ]
}